Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Kurrle
E
E
Dept. of Internal Medicine, University of Ulm, FRG.
Ehninger
G
G
Fackler-Schwalbe
E
E
Freund
M
M
Heil
G
G
Hoelzer
D
D
Link
H
H
Löffler
B
B
Lösch
A
A
Mitrou
P S
PS
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005860:Germany, West / Q000453:epidemiology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000401:mortality; D015993:Life Tables; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D015996:Survival Rate
D003561:Cytarabine; D005047:Etoposide; D003630:Daunorubicin